At the Patient-Centered Outcomes Research Institute (PCORI), we believe comparative clinical effectiveness research (CER) is important and that we have a critical role to play in establishing the nation’s CER priorities. I’m pleased to say that many respondents to the latest National Pharmaceutical Council (NPC) survey think so as well.
While results of CER studies that we and others are funding have yet to be completed, and CER’s ultimate ability to transform our healthcare system is still years away, nearly all respondents in this fourth annual survey agree that CER is here to stay and that it will become increasingly important in aiding decision making. Respondents also indicated that CER has not yet assessed the broader array of outcomes that matter to patients.
These are important insights. The survey tracks the attitudes of researchers, policymakers, employers, business groups, insurers, and health plans. Engaging with these stakeholders – along with patients, caregivers, clinicians, and other providers – and ensuring that the work we fund provides evidence they can trust and use, are essential if CER is to realize its potential in guiding health care.
That’s why Congress authorized PCORI’s establishment as an independent, non-profit organization focused on ensuring that the broad healthcare community is meaningfully engaged in our work. We’re governed by a diverse board that represents all stakeholders. And through an open and collaborative approach to research, we’re identifying the questions patients and other clinical decision makers need answered, so they can make better-informed choices that will lead to better outcomes.
We’ve already awarded $464.4 million to support 279 studies that advance patient-centered CER and we expect to commit another $1 billion over the next two years.